ARAKODA
Peaktafenoquine
NDAORALTABLETPriority Review
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
14
Data completeness
5/8 — Partial
Priority Review
ARAKODA (tafenoquine) is 8-aminoquinoline antimalarial drug [see microbiology ()] . First approved in 2018.
Drug data last refreshed 2d ago
Mechanism of Action
8-aminoquinoline antimalarial drug [see Microbiology ()] .
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (14)
An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older
Started Nov 2024
300 enrolled
Malaria, Vivax
A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria
Started May 2024
1,090 enrolled
Vivax Malaria
Escalating Monthly Doses of Tafenoquine in Healthy Volunteers
Started May 2022
200 enrolled
Prophylaxis
Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria
Started Apr 2018
150 enrolled
Malaria, Vivax
A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria
Started Feb 2017
60 enrolled
Malaria, Vivax
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.